Immunotherapies in CLL Journal Article
| Authors: | Park, J. H.; Brentjens, R. J.; Malek, S. |
| Article Title: | Immunotherapies in CLL |
| Abstract: | Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy. For the moment, allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the only potentially curative treatment for patients with CLL, but it is associated with high rates of treatment-related mortality. Immune-based treatment strategies to augment the cytotoxic potential of T cells offer exciting new treatment options for patients with CLL, and provide a unique and powerful spectrum of tools distinct from traditional chemotherapy. Among the most novel and promising of these approaches are chimeric antigen receptor (CAR)-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy. © 2013 Springer Science+Business Media New York. |
| Keywords: | chimeric antigen receptor; cll; hematopoietic stem cell transplant; cellular immunotherapy |
| Journal Title: | Advances in Experimental Medicine and Biology |
| Volume: | 792 |
| ISSN: | 0065-2598 |
| Publisher: | Springer |
| Date Published: | 2013-01-01 |
| Start Page: | 241 |
| End Page: | 257 |
| Language: | English |
| DOI: | 10.1007/978-1-4614-8051-8_11 |
| PROVIDER: | scopus |
| PUBMED: | 24014300 |
| DOI/URL: | |
| Notes: | Chapter 11 in "Advances in Chronic Lymphocytic Leukemia" (ISBN: 978-1-4614-8050-1)-- "Export Date: 1 November 2013" -- "CODEN: AEMBA" -- "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work